

University of Groningen

Recurrent respiratory papillomatosis

Tjon-Pian-Gi, Robin Edward Adrianus

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Tjon-Pian-Gi, R. E. A. (2016). *Recurrent respiratory papillomatosis: From diagnosis to treatment*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Chapter 4

Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®)

Robin E.A. Tjon Pian Gi¹, Andreas Dietz², Vojko Djukic³, Hans E. Eckel⁴, Gerhard Friedrich⁵, Wojciech Golusinski⁶, Anastasios Hantzakos⁷, George Lawson⁸, Marc Remacle⁹, Heikki Rihkanen¹⁰, Frederik G. Dikkers¹.

1 Department of Otorhinolaryngology/ Head & Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

2 Department of Otorhinolaryngology, University of Leipzig, Leipzig, Germany

3 Clinic for Otorhinolaryngology and Maxillofacial Surgery, Clinical Centre of Serbia, Pasterova 2, Belgrade, Serbia

4 Ear-nose-throat Department, Regionshospitalet Viborg, Viborg, Denmark

5 Department of Otorhinolaryngology, Medical University of Graz, Graz, Austria

6 Department of Otorhinolaryngology, Greater Poland Cancer Centre, Poznan, Poland

7 1st Department of Otorhinolaryngology, Hippocrateion General Hospital, University of Athens, Athens, Greece

8 Department of Otorhinolaryngology, University Hospital of Louvain de Mont-Godinne, Yvoir, Belgium

9 Department of Otorhinolaryngology, University Hospital of Louvain de Mont-Godinne, Yvoir, Belgium

10 Department of Otorhinolaryngology/ Head & Neck Surgery, Helsinki University Hospital, Helsinki, Finland

Recurrent respiratory papillomatosis (RRP) is caused by a human papilloma virus (HPV). It is a rare, sometimes debilitating disease compromising voice and airway. RRP is characterized by a variable course of disease, potentially leading to frequent annual surgical procedures, the number of which may exceed a hundred during the life time. The therapy focuses on surgical removal of the mucosal lesions in order to keep the airway open and the voice satisfactory. By now, there is no curative therapy for the virus infection in itself. As recurrent surgery alone has proven to be insufficient in many cases, adjuvant therapy is increasingly being used. One of the mainstays of adjuvant therapy is the administration of intralesional cidofovir (Vistide®).

Cidofovir is an antiviral agent, registered for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Since 1998 the drug has been used to treat patients with RRP (1). Cidofovir can be regarded as a prodrug. It exerts the antiviral effect by decreasing the efficiency of DNA transcription following incorporation into the growing DNA chain (2). Its use has been advocated in cases of papilloma refractive to repeated surgery, either due to its spread, or to its recurrence rate. Some case reports and series showed the effect of cidofovir treatment with few or no side effects (3-8). The only prospective double blind randomized controlled trial showed a significant improvement in the Voice Handicap Index between the cidofovir and placebo group but failed to show significant benefit in number of procedures performed (9).

On January 31st 2011 alarming news was communicated by Gilead (the producer of cidofovir) concerning very serious side effects of its off-label use (10). The warning included reports on nephrotoxicity, neutropenia, oncogenicity and even some fatalities. The manufacturer emphasized that cidofovir is formulated for intravenous infusion only and the indication is CMV infection of AIDS patients. The manufacturer did not specify the severity of the reported complications, neither the off-label indication of the drug nor its way of administration. Unfortunately, up to the end of May 2011 the above mentioned communication was not received by the laryngologists in most of the countries.

The warning caused a lot of discussion within the European Laryngological Society (ELS). The ELS (having >350 active members) is the main laryngological organization in Europe, representing laryngologists from more than 55 countries

on all continents (www.elsoc.org). The ELS has taken its responsibility and initiated a research project on the side effects of off-label use of cidofovir in RRP patients.

The purpose of such a study is to determine whether there are known nephrotoxic, neutropenic, or oncogenic side effects after having used intralesional cidofovir in patients with RRP. Facts are needed to decide whether or not intralesional use of cidofovir in the larynx is safe or not. Side effects might be dose dependent, and occur as a consequence of the number of administrations, the interval between applications or the cumulative dose. To determine the aforementioned, a multicenter retrospective analysis has been initiated among members of the ELS for which, amongst others, all members of its Scientific Council have been approached.

Parallel to the retrospective study we are conducting an update on reported side effects in the literature.

Reports of the studies will be submitted for publication in the official journal of the ELS, the European Archives of Otorhinolaryngology, Head & Neck Surgery.

References

- (1) Snoeck R, Andrei G, De Clercq E. Specific therapies for human papilloma virus infections. *Curr Opin Infect Dis* 1998 Dec;11(6):733-737.
- (2) Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. *Clin Pharmacokinet* 1999 Feb;36(2):127-143.
- (3) Naiman AN, Ceruse P, Coulombeau B, Froehlich P. Intralesional cidofovir and surgical excision for laryngeal papillomatosis. *Laryngoscope* 2003 Dec;113(12):2174-2181.
- (4) Pransky SM, Albright JT, Magit AE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. *Laryngoscope* 2003 Sep;113(9):1583-1587.
- (5) Dikkers FG. Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir - a prospective study. *Eur Arch Otorhinolaryngol* 2006;263:440-443.
- (6) Bielamowicz S, Villagomez V, Stager SV, Wilson WR. Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. *Laryngoscope* 2002 Apr;112(4):696-699.
- (7) Tanna N, Sidell D, Joshi AS, Bielamowicz SA. Adult intralesional cidofovir therapy for laryngeal papilloma: a 10-year perspective. *Arch Otolaryngol Head Neck Surg* 2008 May;134(5):497-500.
- (8) Wierzbicka M, Jackowska J, Bartochowska A, Jozefiak A, Szyfter W, Kedzia W. Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis. *Eur Arch Otorhinolaryngol* 2011 Apr 26.
- (9) McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. *Ann Otol Rhinol Laryngol* 2008 Jul;117(7):477-483.
- (10) Gillen D. Direct Healthcare Professional Communication regarding serious adverse reactions following off-label use of Vistide. 2011; Available at: <http://www.cbg-meb.nl/NR/rdonlyres/FFB51936-EC22-4180-A213-9E907F06A774/0/VistideDHPCletterJanuary2011.pdf>. Accessed 1/12, 2011.

